Charite-Universitatsmedizin

Berlin 13353

2 studies enrolling now · 6 studies all time

What they study most

AL Amyloidosis, Cell-free DNA, Dermatomyositis, Kidney Transplant Rejection, Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen, Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation, Primary Systemic (AL) Amyloidosis

Studies at this site

• Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation — Recruiting now
• Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen — Recruiting now
• Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring — Recruiting now
• The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis — Stopped early
• Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis — Completed
• The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis — Completed